The Protective Effect of Pentoxifylline on Acute Kidney Injury
Status:
Unknown status
Trial end date:
2017-08-31
Target enrollment:
Participant gender:
Summary
Acute kidney injury (AKI) has a frequency of 7.0 % in hospital inpatients and is especially
common in critically ill patients, in whom the prevalence of acute kidney injury is greater
than 40% at admission to the intensive care unit if sepsis is present. Therefore, alternative
strategies are required to confer better or more complete renoprotection for those who
suffered from AKI.
There had been many studies demonstrated that the phosphodiesterase inhibitor pentoxifylline
(PTX) is a potent anti-inflammatory, anti-proliferative, and anti-fibrotic agent capable of
attenuating experimental renal disease such as drugs, ischemic and sepsis induced AKI. We
thereby design this controlled, non-randomized clinical trial, aiming at investigating the
potential renoprotective efficacy of PTX, as compared to placebo, in 200 patients with AKI.